Canine Lyme disease vaccine
The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.
1. A vaccine composition comprising an immunologically effective amount of organisms from a first strain of B. burgdorferi , wherein first stain is B. burgdorferi ss 50772 (ATCC No. PTA-439) and an immunologically effective amount of organisms of a second strain of B. burgdorferi;
wherein said first strain exhibits an OspC antigen on its cell surface; and
wherein said second strain exhibits an OspA antigen on its cell surface.
2. The vaccine of claim 1 , wherein the immunologically effective amount of organisms from said first strain and said second strain of Borrelia have been inactivated.
3. The vaccine of claim 1 ,
wherein OspC-borreliacidal antibodies are induced in a canine when said canine is immunized with said vaccine composition.
4. The vaccine composition of claim 3 , wherein a significant proportion of the OspC-specific borreliocidal antibodies are specific for OspC7.
5. The vaccine composition of claim 1 , wherein OspC-borreliacidal antibodies and OspA-borreliacidal antibodies are induced in a canine when said canine is immunized with said vaccine composition.
6. The vaccine composition of claim 2 , wherein OspC-borreliacidal antibodies and OspA-borreliacidal antibodies are induced in a canine when said canine is immunized with said vaccine composition.
7. The vaccine composition of claim 1 comprising from about 1×10 4 to about 1×10 10 organisms per milliliter of the first strain and from about 1×10 4 to about 1×10 10 organisms per milliliter of the second strain.
8. The vaccine composition of claim 7 comprising from about 5.0×10 8 to about 5×10 9 organisms per milliliter of the first strain and from about 1.0×10 8 to about 5×10 8 organisms per milliliter of the second strain.
9. The vaccine composition of claim 2 further comprising a pharmaceutically acceptable adjuvant.
10. The vaccine composition of claim 1 further comprising a pharmaceutically acceptable immune stimulant.
11. The vaccine composition of claim 1 further comprising at least one non- Borrelia immunogen for eliciting protective immunity to a non- Borrelia pathogen.
12. The vaccine composition of claim 11 , wherein the non- Borrelia immunogen is selected from the group consisting of canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, canine coronavirus, canine influenza virus, Leptospira serovars, Leishmania organisms, Bordetella bronchiseptica, Mycoplasma species, rabies virus, Ehrlichia canis , an anaplasma organisim, and combinations thereof.
13. The vaccine composition of claim 12 , wherein the Leptospira serovars are selected from the group consisting of Leptospira kirschneri serovar grippotyphosa, Leptospira interrogans serovar canicola, Leptospira interrogans serovar icterohaemorrhagiae, Leptospira interrogans serovar pomona, and combinations thereof.
14. The vaccine composition of claim 12 , wherein the Mycoplasma species comprises Mycoplasma cynos.
15. The vaccine composition of claim 2 comprising from about 1×10 4 to about 1×10 10 organisms per milliliter of the first strain and from about 1×10 4 to about 1×10 10 organisms per milliliter of the second strain.
16. The vaccine composition of claim 15 comprising from about 5.0×10 8 to about 5×10 9 organisms per milliliter of the first strain and from about 1.0×10 8 to about 5×10 8 organisms per milliliter of the second strain.
17. A method of immunizing a canine against a pathogenic Borrelia genospecies comprising injecting the canine with an immunologically effective amount of the vaccine of claim 2 .
18. A method of immunizing a canine against a pathogenic Borrelia genospecies comprising injecting the canine with an immunologically effective amount of the vaccine of claim 1 .
19. The method of claim 18 wherein the second strain is B. burgdorferi sensu stricto.
20. The method of claim 18 wherein the second strain is selected from the group consisting of B. burgdorferi ss S-1-10 (ATCC No. PTA-1680), B. burgdorferi ss B-31 (ATCC No. 35210), B. afzelii (ATCC No. 51567), B. garinii (ATCC Nos. 51383 or 51991), B. burgdorferi ss DK7, B. burgdorferi ss 61 BV3, B. burgdorferi ss ZS7, B. burgdorferi ss Pka, B. burgdorferi ss IP1, IP2, IP3, B. burgdorferi ss HII, B. burgdorferi ss P1F, B. burgdorferi ss Mil, B. burgdorferi ss 20006, B. burgdorferi ss 212, B. burgdorferi ss ESP1, B. burgdorferi ss Ne-56, B. burgdorferi ss Z136, B. burgdorferi ss ia, and combinations thereof.
21. The method of claim 18 wherein the immunized canine produces borreliacidal antibodies.
22. The method of claim 18 wherein the canine is injected with from about 5×10 7 to about 5×10 9 of each respective strain of Borrelia species.
23. The method of claim 17 wherein the immunized canine produces borreliacidal antibodies.